Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 [tarenflurbil; Flurizan] on Measures of Cognition, Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimer's Type

Trial Profile

Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 [tarenflurbil; Flurizan] on Measures of Cognition, Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimer's Type

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Jan 2010

At a glance

  • Drugs Tarenflurbil (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ActEarliAD-US
  • Most Recent Events

    • 16 Dec 2009 Primary endpoint 'Alzheimer's Disease Assessment Scale' has not been met.
    • 16 Dec 2009 Primary endpoint 'Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory' has not been met.
    • 16 Dec 2009 Primary endpoint 'Cognitive function tests' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top